Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 1-Year High – Time to Buy?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $131.94 and last traded at $131.89, with a volume of 625284 shares traded. The stock had previously closed at $131.81.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ITCI. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Ten analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Intra-Cellular Therapies has an average rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Trading Up 0.1 %

The stock has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.59 and a beta of 0.69. The stock has a 50-day simple moving average of $129.12 and a 200 day simple moving average of $99.80.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Intra-Cellular Therapies

Hedge funds have recently modified their holdings of the stock. Accredited Wealth Management LLC acquired a new stake in Intra-Cellular Therapies during the fourth quarter valued at $28,000. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth about $32,000. GAMMA Investing LLC lifted its holdings in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at approximately $96,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Intra-Cellular Therapies in the 3rd quarter valued at approximately $97,000. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.